Leaps by Bayer
Edit

Leaps by Bayer

https://leaps.bayer.com
Last activity: 18.09.2026
Active
Leaps by Bayer invests in paradigm-shifting advances in the life sciences – targeting the breakthroughs that could fundamentally change the world for the better. Our approach is making significant and sustained investments in disruptive biotechnologies that could have the greatest impact on humanity. Leaps aims to conquer ten huge challenges in the areas of health and agriculture. Some people call them impossible. We call them “leaps.”
Portfolio
8
Mentions
92
Location: Germany, Berlin
Employees: 11-50
Founded date: 2015
Investment Type: Venture Capital
Investment Stage: Series A; Series B

Portfolio 8

DateNameWebsiteTotal RaisedLocation
11.06.2026Leaf Agric...withleaf.io$30.67MUnited Sta...
10.06.2026SonoThera,...sonothera.com$310.75MUnited Sta...
15.10.2025WellTheorywelltheory.com$26.2MUnited Sta...
03.11.2022NuCicernucicer.com$18.5MUnited Sta...
22.03.2022Affini-T T...affinittx.com$175MUnited Sta...
27.05.2021Ada Healthada.com$257.15MCanada
24.03.2021amforaamforainc.com$6M-
12.11.2020Metagenomimetagenomi.co$415MUnited Sta...

Mentions in press and media 92

DateTitleDescription
19.09.2026Agricultural Innovation Takes Root: Robigo Bio Secures Major FundingRobigo Bio closed Series A funding, led by Leaps by Bayer. This investment accelerates the commercial launch of its revolutionary crop biologicals. Robigo engineers microbes. These solutions combat devastating crop diseases, including soybe...
18.09.2026Robigo Announces Series A Funding CAMBRIDGE, MA, Robigo, a biotechnology company engineering no-compromise biological solutions for crop protection, has announced a Series A funding. >> Click here for more funding data on Robigo >> To export Robigo funding data...
17.09.2026Robigo Bio eyes commercialization for its ag biologicals with Leaps by Bayer investmentRobigo Bio has closed a Series A financing round to accelerate the commercial launch of its crop biological products, which the company claims can match or outperform synthetic chemistries instead of merely complementing them. Importantly, ...
17.09.2026AgriFood Signals: Syngenta HK IPO, Terradot and Google do enhanced rock weathering, Corteva split lawsuitsAgFunderNews rounds up the most important fundings, mergers, acquisitions, closures, and industry buzz in agtech and foodtech. Funding news 🇪🇸 Cofides takes a stake in Elian with an injection of 40 million Democrata 🇨🇱 Loads secures $15m cr...
16.07.2026AgriFood Signals: Uber’s $14.8bn bid for Delivery Hero, Hippo Harvest banks $30m, agentic AI for agAgFunderNews rounds up the most important fundings, mergers, acquisitions, closures, and industry buzz in agtech and foodtech. Funding news 🇺🇸 Marc Lore says Wonder is gearing up for an IPO after raising $650 million at a $9 billion valuati...
15.07.2026Sabanto Raises Series B To Scale Autonomous Farming TechnologySabanto, an agricultural technology company developing autonomous retrofit systems for farm equipment, has raised an oversubscribed Series B funding round. The financial terms of the round were not disclosed. Leaps by Bayer led the financin...
14.07.2026Leaps By Bayer backs Sabanto to bring ‘practical autonomy to more farms’Sabanto, best known for its autonomy retrofit system for agriculture, has raised an oversubscribed Series B round to bring “practical autonomy to more farms,” according to founder and CEO Craig Rupp. “We believe autonomy should reduce capit...
14.07.2026Sabanto Secures Oversubscribed Series B AMES, IA, Sabanto, a leader in autonomous retrofit technology for agriculture, today announced an oversubscribed Series B funding. >> Click here for more funding data on Sabanto >> To export Sabanto funding data to PDF and Exce...
14.07.2026Sabanto Closes Series B FundingSabanto, a Chicago, IL-based company which specializes in autonomous retrofit technology for agriculture, raised an undisclosed amount in Series B funding. The round was led by Leaps by Bayer with participation by Sustainable Forward Capita...
02.07.2026Celea Therapeutics Raises $180M in FinancingCelea Therapeutics, a Boston, MA-based clinical-stage biopharmaceutical company dedicated to advancing treatments for people with serious respiratory diseases, closed a $180m financing. Participants included RA Capital Management, Leaps by ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In